Stanford researchers engineered PTERi, a nanomolar-potency inhibitor targeting PTER, an enzyme that breaks down N-acetyltaurine, a natural appetite-suppressing metabolite. The inhibitor demonstrated over 100-fold selectivity for PTER versus similar enzymes and reduced feeding behavior in obese mice while enhancing weight loss from GLP-1 receptor agonists and preventing weight regain after discontinuation. This represents a potentially transformative approach to obesity treatment by pharmacologically preserving the body's own satiety signals rather than introducing external compounds. The discovery that PTER shares structural similarities with histone deacetylases opens new therapeutic possibilities and could accelerate drug development timelines by repurposing existing chemical scaffolds. However, the research remains in early preclinical stages with mouse studies only, and the long-term safety profile of chronic PTER inhibition is unknown. The combination potential with existing GLP-1 therapies like semaglutide could address a major clinical challenge—the weight regain that typically occurs when these expensive medications are discontinued. This mechanistic innovation in metabolic regulation could reshape obesity pharmacotherapy if human trials confirm efficacy and safety.